Physical inactivity has consistently been shown to be one of the most powerful, modifiable risk factors for all causes of death and disease, alongside smoking and obesity.
This interactive body map brings together scientific evidence on the links between lack of physical activity and disease.
Click on the coloured dots on the body, or choose a specific disease from the dropdown menu, or cycle through all diseases via the next and previous buttons.
To use the map, click on any of the coloured dots on the body, or choose a specific disease from the dropdown menu. You can also filter by disease or condition type.
This is the first in our package on the benefits of exercise. Read other articles in the package here.
For a copy of the data and notes on the methodology used for the calculations, please visit The Conversation’s GitHub page.
Carol Maher receives funding from the National Health and Medical Research Council and the National Heart Foundation.
Tim Olds receives funding from the ARC and the NHMRC.
This article was originally published on The Conversation. Read the original article.


Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
CDC Acting Director Urges Measles Vaccination as U.S. Cases Surge in 2026
Trump Reportedly Approves Plan to Remove FDA Commissioner Marty Makary Amid Growing Controversies
Medicare to Cover GLP-1 Weight-Loss and Diabetes Drugs Starting July 1
Moderna to Pay Up to $2.25B to Settle LNP Patent Dispute Over COVID-19 Vaccine Technology
U.S. Officials Express Optimism Over New CDC Director Selection Amid Vaccine Policy Turmoil
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine
The four types of dementia most people don’t know exist
FDA Warns Novo Nordisk Over Misleading Ozempic Ad Claims
RFK Jr. Faces Scrutiny Over David Geier’s HHS Role and Vaccine Review Work
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval
Intermittent fasting doesn’t have an edge for weight loss, but might still work for some
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma
FDA Biologics Chief Vinay Prasad to Leave Agency in April Amid Policy Disputes 



